drugset / Trial / NCT00100724
Trial of rPA-102 Vaccine in Healthy Adult Volunteers
Phase 2
Completed
480 enrolled
VaxGen
Centers for Disease Control and Prevention · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to assess the safety and immunogenicity of rPA102 vaccine given intramuscularly at 0 and 4 weeks over 2 dose ranges and 4 adjuvant levels.
Timeline
- Start
- 2004-04
- Primary completion
- —
- Completion
- 2005-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rPA102 | Vaccine | — | Intramuscular |